Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?
作者信息
Wood Peter
出版信息
Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):1-3. doi: 10.1007/s00210-011-0694-y. Epub 2011 Oct 4.
Abstract
摘要
相似文献
1
Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?替加色罗治疗以便秘为主的肠易激综合征。风险是否大于益处？
Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):1-3. doi: 10.1007/s00210-011-0694-y. Epub 2011 Oct 4.
2
Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome.替加色罗用于以便秘为主的肠易激综合征患者的长期安全性。
Aliment Pharmacol Ther. 2002 Oct;16(10):1701-8. doi: 10.1046/j.1365-2036.2002.01347.x.
3
Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.替加色罗治疗亚太地区便秘型肠易激综合征患者的安全性、耐受性及满意度
J Gastroenterol Hepatol. 2007 Aug;22(8):1190-8. doi: 10.1111/j.1440-1746.2007.04955.x. Epub 2007 May 24.
4
Review of tegaserod in the treatment of irritable bowel syndrome.替加色罗治疗肠易激综合征的综述。
Expert Opin Pharmacother. 2004 Nov;5(11):2369-79. doi: 10.1517/14656566.5.11.2369.
5
Safety and tolerability of tegaserod in irritable bowel syndrome management.替加色罗在肠易激综合征治疗中的安全性和耐受性。
J Am Pharm Assoc (2003). 2004 Jan-Feb;44(1):41-51. doi: 10.1331/154434504322713228.
6
A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation.一项评估重复使用替加色罗治疗便秘型肠易激综合征女性患者的疗效和安全性的随机对照试验。
Gut. 2005 Dec;54(12):1707-13. doi: 10.1136/gut.2005.070789. Epub 2005 Jul 14.
7
Tegaserod and ischemic colitis.
N Engl J Med. 2004 Sep 23;351(13):1361-4; discussion 1361-4. doi: 10.1056/NEJM200409233511324.
8
Tegaserod for constipation-predominant irritable bowel syndrome.替加色罗用于以便秘为主的肠易激综合征
Pharmacotherapy. 2007 Feb;27(2):267-77. doi: 10.1592/phco.27.2.267.
9
Review article: the safety profile of tegaserod.综述文章：替加色罗的安全性概况
Aliment Pharmacol Ther. 2004 Nov;20 Suppl 7:25-30. doi: 10.1111/j.1365-2036.2004.02182.x.
10
[Tegaserod in treatment of women with irritable bowel syndrome].替加色罗治疗肠易激综合征女性患者
Ugeskr Laeger. 2007 Jun 4;169(23):2190-2.
引用本文的文献
1
Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.匹维溴铵 100mg 联合西甲硅油 300mg 治疗肠易激综合征腹痛腹胀的疗效：一项随机、安慰剂对照试验。
J Clin Gastroenterol. 2020 Apr;54(4):e30-e39. doi: 10.1097/MCG.0000000000001242.
2
Recent Updates on the Treatment of Constipation.便秘治疗的最新进展
Intest Res. 2015 Oct;13(4):297-305. doi: 10.5217/ir.2015.13.4.297. Epub 2015 Oct 15.
3
Novel pharmacological therapies for management of chronic constipation.新型药理学疗法治疗慢性便秘。
J Clin Gastroenterol. 2014 Jan;48(1):21-8. doi: 10.1097/01.mcg.0000436440.05887.02.
本文引用的文献
1
Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.普芦卡必利治疗便秘型肠易激综合征成人患者
Dig Dis Sci. 2011 Jun;56(6):1619-25. doi: 10.1007/s10620-011-1702-2. Epub 2011 Apr 27.
2
Therapy options in irritable bowel syndrome.肠易激综合征的治疗选择。
Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1402-11. doi: 10.1097/MEG.0b013e3283405a17.
3
New horizons in vascular biology and thrombosis: Highlights from EMVBM 2009.
Thromb Haemost. 2010 Sep;104(3):421-3. doi: 10.1160/TH10-07-0485. Epub 2010 Aug 5.
4
The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.经皮冠状动脉介入治疗患者血小板功能检测的循证依据。
Circ Cardiovasc Interv. 2010 Jun 1;3(3):277-83; discussion 283. doi: 10.1161/CIRCINTERVENTIONS.109.928861.
5
Investigations on 5-HT₄ receptor expression and effects of tegaserod on human platelet aggregation in vitro.5-HT₄ 受体表达的研究及替加色罗对人血小板聚集的体外作用。
Am J Ther. 2010 Nov-Dec;17(6):543-52. doi: 10.1097/MJT.0b013e3181b63f21.
6
A placebo-controlled trial of prucalopride for severe chronic constipation.普芦卡必利治疗严重慢性便秘的安慰剂对照试验。
N Engl J Med. 2008 May 29;358(22):2344-54. doi: 10.1056/NEJMoa0800670.
7
Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test?
J Thromb Haemost. 2007 Sep;5(9):1835-8. doi: 10.1111/j.1538-7836.2007.02655.x.
8
Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.肠易激综合征患者的治疗选择：传统与新型5-羟色胺能疗法对比
Neurogastroenterol Motil. 2004 Dec;16(6):701-11. doi: 10.1111/j.1365-2982.2004.00550.x.
9
Review article: the safety profile of tegaserod.综述文章：替加色罗的安全性概况
Aliment Pharmacol Ther. 2004 Nov;20 Suppl 7:25-30. doi: 10.1111/j.1365-2036.2004.02182.x.
10
Assessment of platelet activation in myeloproliferative disorders with complementary techniques.
Blood Coagul Fibrinolysis. 2004 Apr;15(3):235-40. doi: 10.1097/00001721-200404000-00006.
Zotero 插件